Vaccitech Newsroom
News & updates
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
Oxford, UK - Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces the appointment...
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient...
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
Oxford, UK - Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has...
Vaccitech Appoints Two Independent Board Directors
Oxford, UK - Vaccitech Ltd., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the appointment of two new...
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient...
European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine
Oxford, UK - Vaccitech Ltd announces that the European Medicines Agency (EMA) has today recommended the conditional marketing authorisation of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. Distribution will...
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
Oxford, UK - Vaccitech Ltd announces that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The vaccine was...
First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy
Oxford, UK - Vaccitech’s scientific founders at University of Oxford and Astrazeneca announce the first peer-reviewed publication of Phase 3 data from studies of a vaccine against the coronavirus in the Lancet. The vaccine, ChAdOx1 nCoV-19, also known as AZD1222, was...
Vaccitech Chief Scientific Officer Dr. Thomas Evans on COVID-19 vaccination
In an interview with Sky News, Vaccitech Chief Scientific Officer, Dr. Thomas Evans, discusses the regulatory and public health aspects of Emergency Use Authorisation of COVID-19 vaccines. The interview aired on the 2nd of December 2020.
Vaccitech Co-Founder Professor Adrian Hill on Developing a Covid-19 Vaccine
Following the news that AstraZeneca, the University of Oxford, and Vaccitech's vaccine for COVID-19 is highly effective and safe, Vaccitech co-founder Professor Adrian Hill talked to Tom Hulme, General Partner at Vaccitech shareholder GV, Vidu Shanmugarajah, Partner...